Physician profile
Sithu Lin
NPI 1023417649
$1,006.23
in general payments reported to CMS, 2019-2025
12 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.32 · 2022: $92.00 · 2023: $13.60 · 2024: $627 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $45.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.04 |
| Education | $45.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $379.89 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.08 | 2024 | Jardiance |
| Baxter Healthcare | $92.00 | 2022 | |
| Calliditas Therapeutics US INC. | $73.73 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $41.07 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $33.00 | 2024-2025 | Farxiga |
| Ascendis Pharma Endocrinology INC | $27.96 | 2025 | Yorvipath |
| Otsuka America Pharmaceutical, INC. | $25.10 | 2024 | Jynarque |
| Amgen INC. | $22.24 | 2024 | Tavneos, Aranesp, Parsabiv |
| Kyowa Kirin, INC. | $21.14 | 2025 | |
| Akebia Therapeutics INC | $16.77 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $15.25 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sithu Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.